ALFA Filings
Every announcement, straight from the exchange
Every Concord Biotech earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
7 announcements
Revenue grew 25% YoY driven by API demand, but gross margins contracted 400bps due to rising solvent costs and geopolitical disruptions.
Q2FY27 consolidated revenue ₹309.1 Cr (+25%) and PAT ₹69.6 Cr (+10%); H1 revenue ₹566.6 Cr (+26%). Margins compressed; Inspira dermatology division launched.
Concord reports a strong 26% revenue recovery in Q1FY27, pivoting from a challenging FY26 despite previous procurement delays.
Concord Biotech reported strong Q1FY27 consolidated performance with 26% revenue growth and 31% PAT growth, driven by a 46% surge in exports and expanding market share in niche fermentation APIs.
Concord Biotech reported a challenging FY26 with a 12% revenue decline and 30% PAT drop due to geopolitical headwinds, tender delays, and regulatory holdups. Management remains optimistic for a stronger FY27.
FY26 was a rough year marked by geopolitical disruptions and US procurement slowdowns. Management pivots to a recovery narrative for FY27, banking on new injectable facilities and US direct marketing to reverse recent de-growth.
Concord Biotech reported a challenging FY26 with consolidated revenue at ₹1,054.9 Cr (-12% YoY) and PAT at ₹259.2 Cr (-30% YoY) due to procurement delays and geopolitical issues.